Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
Discover Oncology
Erschienen in: Discover Oncology 5/2018

09.07.2018 | Review

RAGE and Its Ligands: Molecular Interplay Between Glycation, Inflammation, and Hallmarks of Cancer—a Review

verfasst von: Gowri Palanissami, Solomon F. D. Paul

Erschienen in: Discover Oncology | Ausgabe 5/2018

Einloggen, um Zugang zu erhalten

Abstract

Risk of cancer especially of colon, breast, and pancreas is high in diabetic and obese patients, with potential involvement of augmented expression of RAGE (receptor for advanced glycation end products) and its ligands, namely AGEs (advanced glycation end products), HMGB1 (high-mobility group box 1 protein), and S100 group of proteins. Studies have reported the involvement of RAGE activation by its ligands in growth and survival of cancers, including metastasis and poor prognosis. We propose that this receptor-ligand axis provides the molecular link between certain pre-existing states as hypoxia, hyperglycemia, glycation, inflammation, oxidative stress, and onset of cancers. The chronic inflammatory, hyperglycemic milieu accompanied by glycoxidative stress as in diabetes and obesity, concomitant with the formation of RAGE ligands, instigates RAGE and cancer stem cells, leading to the oncogenic transformation of normal and pre-malignant tissues towards development of neoplasms. We have aimed to elucidate the complete signalling map initiated upon RAGE-ligand splicing, from oncogenesis to progression, epithelial-mesenchymal transition, invasion, cancer stem cell renewal, chemo-resistance, and cancer relapse. We have attributed the complex molecular functions of RAGE-ligand signalling cues to every aspect of cancer promotion, explaining the central network in bridging glycation, inflammation, oxidation, and the hallmarks of cancer. Underlining the substantial requisite for anti-neoplastic agents targeting RAGE and its ligands, we have explicitly discoursed RAGE and its allied components (AGEs, soluble RAGE, RAGE gene polymorphisms) as potential diagnostic and prognostic biomarkers for prompt detection of cancers and implication in impending RAGE-ligand directed, novel combinatorial, and targeted onco-therapeutics.
Literatur
1.
World Health Organization. Breast cancer estimated incidence, mortality and prevalence worldwide in 2012. 2012. URL: http://​globocan iarc fr/old/FactSheets/cancers/breast-new asp [WebCite Cache ID 6aKrqTle9]
2.
Mathupala SP, Ko YH, Pedersen PL (2010) The pivotal roles of mitochondria in cancer: Warburg and beyond and encouraging prospects for effective therapies. BBA-Bioenergetics 1797(6):1225–1230PubMedCrossRef
3.
4.
5.
Turner DP (2015) Advanced glycation end-products: a biological consequence of lifestyle contributing to cancer disparity. Cancer Res 75(10):1925–1929PubMedPubMedCentralCrossRef
6.
Heijst JWJ, Niessen HWM, Hoekman K, Schalkwijk CG (2005) Advanced glycation end products in human cancer tissues: detection of Nε-(carboxymethyl) lysine and argpyrimidine. Ann N Y Acad Sci 1043(1):725–733PubMedCrossRef
7.
Ashraf JM, Shahab U, Tabrez S, Lee EJ, Choi I, Yusuf MA, Ahmad S (2016) DNA glycation from 3-deoxyglucosone leads to the formation of AGEs: potential role in cancer auto-antibodies. Cell Biochem Biophys 74(1):67–77PubMedCrossRef
8.
Synold T, Xi B, Wuenschell GE, Tamae D, Figarola JL, Rahbar S, Termini J (2008) Advanced glycation end products of DNA: quantification of N 2-(1-carboxyethyl)-2′-deoxyguanosine in biological samples by liquid chromatography electrospray ionization tandem mass spectrometry. Chem Res Toxicol 21(11):2148–2155PubMedPubMedCentralCrossRef
9.
Yamagishi S, Matsui T, Fukami K (2015) Role of receptor for advanced glycation end products (RAGE) and its ligands in cancer risk. Rejuvenation Res 18(1):48–56PubMedCrossRef
10.
Logsdon CD, Fuentes MK, Huang EH, Arumugam T (2007) RAGE and RAGE ligands in cancer. Curr Mol Med 7(8):777–789PubMedCrossRef
11.
12.
13.
Wei Y, Chen L, Chen J, Ge L, He RQ (2009) Rapid glycation with D-ribose induces globular amyloid-like aggregations of BSA with high cytotoxicity to SH-SY5Y cells. BMC Cell Biol 10(1):10PubMedPubMedCentralCrossRef
14.
Baraka-Vidot J, Guerin-Dubourg A, Bourdon E, Rondeau P (2012) Impaired drug-binding capacities of in vitro and in vivo glycated albumin. Biochimie 94(9):1960–1967PubMedCrossRef
15.
Ansari NA, Ali R (2011) Physicochemical analysis of poly-L-lysine: an insight into the changes induced in lysine residues of proteins on modification with glucose. IUBMB Life 63(1):26–29PubMedCrossRef
16.
Bao J-M, He M-Y, Liu Y-W, Lu Y-J, Hong Y-Q, Luo H-H, Ren Z-L, Zhao S-C, Jiang Y (2015) AGE/RAGE/Akt pathway contributes to prostate cancer cell proliferation by promoting Rb phosphorylation and degradation. Am J Cancer Res 5(5):1741PubMedPubMedCentral
17.
Yaser AM, Huang Y, Zhou RR, Hu GS, Xiao MF, Huang ZB, Duan CJ, Tian W, Tang DL, Fan XG (2012) The role of receptor for advanced glycation end products (RAGE) in the proliferation of hepatocellular carcinoma. Int J Mol Sci 13(5):5982–5997PubMedPubMedCentralCrossRef
18.
Matou-Nasri S, Sharaf H, Wang Q, Almobadel N, Rabhan Z, Al-Eidi H, Yahya WB, Trivilegio T, Ali R, Al-Shanti N, Ahmed N (2017) Biological impact of advanced glycation endproducts on estrogen receptor-positive MCF-7 breast cancer cells. Biochim Biophys Acta (BBA) Mol Basis Dis 1863(11):2808–2820CrossRef
19.
Fritz G (2011) RAGE: a single receptor fits multiple ligands. Trends Biochem Sci 36(12):625–632PubMedCrossRef
20.
Xue J, Rai V, Singer D, Chabierski S, Xie J, Reverdatto S, Burz David S, Schmidt AM, Hoffmann R, Shekhtman A (2011) Advanced glycation end product recognition by the receptor for AGEs. Structure 19(5):722–732PubMedPubMedCentralCrossRef
21.
Cai W, Ramdas M, Zhu L, Chen X, Striker GE, Vlassara H (2012) Oral advanced glycation endproducts (AGEs) promote insulin resistance and diabetes by depleting the antioxidant defenses AGE receptor-1 and sirtuin 1. Proc Natl Acad Sci 109(39):15888–15893PubMedCrossRefPubMedCentral
22.
Nedić O, Rattan SIS, Grune T, Trougakos IP (2013) Molecular effects of advanced glycation end products on cell signalling pathways, ageing and pathophysiology. Free Radic Res 47(sup1):28–38PubMedCrossRef
23.
Ramasamy R, Vannucci SJ, Yan SS, Herold K, Yan SF, Schmidt AM (2005) Advanced glycation end products and RAGE: a common thread in aging, diabetes, neurodegeneration, and inflammation. Glycobiology 15(7):16R–28RPubMedCrossRef
24.
Srikanth V, Maczurek A, Phan T, Steele M, Westcott B, Juskiw D, Münch G (2011) Advanced glycation endproducts and their receptor RAGE in Alzheimer’s disease. Neurobiol Aging 32(5):763–777PubMedCrossRef
25.
Diamanti-Kandarakis E, Piperi C, Patsouris E, Korkolopoulou P, Panidis D, Pawelczyk L, Papavassiliou AG, Duleba AJ (2007) Immunohistochemical localization of advanced glycation end-products (AGEs) and their receptor (RAGE) in polycystic and normal ovaries. Histochem Cell Biol 127(6):581–589PubMedCrossRef
26.
Gomes R, Silva MS, Quintas A, Cordeiro C, Freire A, Pereira P, Martins A, Monteiro E, Barroso E, Freire AP (2005) Argpyrimidine, a methylglyoxal-derived advanced glycation end-product in familial amyloidotic polyneuropathy. Biochem J 385(2):339–345PubMedPubMedCentralCrossRef
27.
28.
Ko S-Y, Ko H-A, Shieh T-M, Chang W-C, Chen H-I, Chang S-S, Lin I-H (2014) Cell migration is regulated by AGE-RAGE interaction in human oral cancer cells in vitro. PLoS One 9(10):e110542PubMedPubMedCentralCrossRef
29.
Nasser MW, Wani NA, Ahirwar DK, Powell CA, Ravi J, Elbaz M, Zhao H, Padilla L, Zhang X, Shilo K (2015) RAGE mediates S100A7-induced breast cancer growth and metastasis by modulating the tumor microenvironment. Cancer Res 75(6):974–985PubMedPubMedCentralCrossRef
30.
Kang R, Hou W, Zhang Q, Chen R, Lee YJ, Bartlett DL, Lotze MT, Tang D, Zeh HJ (2014) RAGE is essential for oncogenic KRAS-mediated hypoxic signaling in pancreatic cancer. Cell Death Dis 5(10):e1480PubMedPubMedCentralCrossRef
31.
Hiba Z, Borden Katherine LB (2013) Mechanisms and insights into drug resistance in cancer. Front Pharmacol 4
32.
Housman G, Byler S, Heerboth S, Lapinska K, Longacre M, Snyder N, Sarkar S (2014) Drug resistance in cancer: an overview. Cancers 6(3):1769–1792PubMedPubMedCentralCrossRef
33.
Shi W, Jiang T, Nuciforo P, Hatzis C, Holmes E, Harbeck N, Sotiriou C, Peña L, Loi S, Rosa DD (2017) Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial. Ann Oncol 28(1):128–135PubMed
34.
Sullivan Lucas B, Gui Dan Y, Vander Heiden Matthew G (2016) Altered metabolite levels in cancer: implications for tumour biology and cancer therapy. Nat Rev Cancer 16(11):680–693PubMedCrossRef
35.
Pelicano H, Dai J, Liu J, Pusztai L, Hammoudi N, Huang P, Xu R-H, Zhang W (2014) Mitochondrial dysfunction in some triple-negative breast cancer cell lines: role of mTOR pathway and therapeutic potential. Breast Cancer Res 16(5):434PubMedPubMedCentralCrossRef
36.
Fais S, Venturi G, Gatenby B (2014) Microenvironmental acidosis in carcinogenesis and metastases: new strategies in prevention and therapy. Cancer Metastasis Rev 33(4):1095–1108PubMedPubMedCentralCrossRef
37.
Kellenberger LD, Bruin JE, Greenaway J, Campbell NE, Moorehead RA, Holloway AC, Petrik J (2010) The role of dysregulated glucose metabolism in epithelial ovarian cancer. J Oncol:2010
38.
39.
Gatenby Robert A, Gawlinski Edward T (2003) The glycolytic phenotype in carcinogenesis and tumor invasion. Cancer Res 63(14):3847–3854PubMed
40.
Ansari NA, Rasheed Z (2009) Non-enzymatic glycation of proteins: from diabetes to cancer. Biochem (Mosc) Suppl Ser B Biomed Chem 3(4):335–342
41.
Poulsen MW, Hedegaard RV, Andersen JM, de Courten B, Bügel S, Nielsen J, Skibsted LH, Dragsted LO (2013) Advanced glycation endproducts in food and their effects on health. Food Chem Toxicol 60:10–37PubMedCrossRef
42.
Claudia L-C, Karen C-N (2010) Dietary advanced glycation end products and aging. Nutrients 2(12):1247–1265CrossRef
43.
Dion F, Laura S, Walter Katherine R, Nogueira Lourdes M, Hleb F, Turner Ryan Y, Mahtabuddin A, Salley Judith D, Ford Marvella E, Findlay VJ (2014) AGE metabolites: a biomarker linked to cancer disparity? Cancer Epidemiol Biomarkers Prev 23(10):2186–2191
44.
Junjeong C, Do Hee K, Hee JW, Seung KJ (2013) Metabolic interaction between cancer cells and stromal cells according to breast cancer molecular subtype. Breast Cancer Res 15(5):R78CrossRef
45.
46.
Da W, Tingting L, Gengtai Y, Zhiyong S, Yanfeng H, Tingyu M, Jiang Y, Sihao L, Hao L, Guoxin L (2015) Overexpression of the receptor for advanced glycation endproducts (RAGE) is associated with poor prognosis in gastric cancer. PLoS One 10(4):e0122697CrossRef
47.
Selvia S, Tarek A, Amr A (2017) Differentiation of RAGE expression in primary tumors and lymph node metastatic deposits of breast carcinoma. Imp J Interdiscip Res 3(6)
48.
Korwar Arvind M, Bhonsle Hemangi S, Chougale Ashok D, Kote Sachin S, Gawai Kachru R, Ghole Vikram S, Koppikar Chaitanyananda B, Kulkarni Mahesh J (2012) Analysis of AGE modified proteins and RAGE expression in HER2/neu negative invasive ductal carcinoma. Biochem Biophys Res Commun 419(3):490–494PubMedCrossRef
49.
Bing P, Hui R, Yijing M, Donghui L, Baoqi Y, Liang J, Ling P, Jing L, Liangui Y, Xiaofeng L (2012) High-density lipoprotein of patients with type 2 diabetes mellitus elevates the capability of promoting migration and invasion of breast cancer cells. Int J Cancer 131(1):70–82CrossRef
50.
Jin PL, Lin L, Qi Z, Yan ZR, Feng SW, Ying S (2012) Increased blood glycohemoglobin A1c levels lead to overestimation of arterial oxygen saturation by pulse oximetry in patients with type 2 diabetes. Cardiovasc Diabetol 11(1):110CrossRef
51.
Philippe R, Emmanuel B (2011) The glycation of albumin: structural and functional impacts. Biochimie 93(4):645–658CrossRef
52.
Rouf MA, Safia H, Farzana K, Khursheed A, Asif A (2015) Structural changes in histone H2A by methylglyoxal generate highly immunogenic amorphous aggregates with implications in auto-immune response in cancer. Glycobiology 26(2):129–141
53.
Saheem A, Kiran D, Uzma S, Khursheed A, Asif A (2011) Genotoxicity and immunogenicity of DNA-advanced glycation end products formed by methylglyoxal and lysine in presence of Cu2+. Biochem Biophys Res Commun 407(3):568–574CrossRef
54.
55.
Uetz-von AE, Michael K, Günter F, Legler DF (2008) V domain of RAGE interacts with AGEs on prostate carcinoma cells. Prostate 68(7):748–758CrossRef
56.
Rabbani Naila, Thornalley Paul J (2014). Dicarbonyl proteome and genome damage in metabolic and vascular disease. Biochem Soc Trans.
57.
Deng R, Wu H, Hui R, Kong X, Hu L, Wang X, Qing S (2017) Glucose-derived AGEs promote migration and invasion of colorectal cancer by up-regulating Sp1 expression. BBA-Gen Subjects 1861(5):1065–1074CrossRef
58.
Shun-Yao K, Hshin-An K, Tzong-Ming S, Tzong-Cherng C, Chen H-I, Yi-Ting C, Yu Y-H, Yang S-H, Shu-Shing C (2017) Advanced glycation end products influence oral cancer cell survival via Bcl-xl and Nrf-2 regulation in vitro. Oncol Lett 13(5):3328–3334CrossRef
59.
Jun-Ichi T, Sho-Ichi Y, Masayoshi T (2010) Cancer malignancy is enhanced by glyceraldehyde-derived advanced glycation end-products. J Oncol:2010
60.
Riichiro A, Sho-ichi Y (2008) AGE-RAGE system and carcinogenesis. Curr Pharm Des 14(10):940–945CrossRef
61.
Lin J-A, Wu C-H, Gow-Chin Y (2017) Methylglyoxal displays colorectal cancer-promoting properties in the murine models of azoxymethane and CT26 isografts. Free Radic Biol Med
62.
Dachun Y, Michael B (2010) Hyperglycemia-induced reactive oxygen species increase expression of the receptor for advanced glycation end products (RAGE) and RAGE ligands. Diabetes 59(1):249–255CrossRef
63.
Kuang CY, Rusliza B, Herni T, Hing TT, Norshariza N (2013) Receptor for advanced glycation end products and its involvement in inflammatory diseases. Int J Inflamm:2013
64.
Christiane O, Kathleen J, Elisa H, Navarrete SA, Tilman G, Andreas S (2014) Role of advanced glycation end products in cellular signaling. Redox Biol 2:411–429CrossRef
65.
Christoffer G, Astrid R, Moritz D, Julia N, Gerhard F, Karin M-D, Alexander E, Bernd A, Bierhaus Angelika NPP (2008) RAGE signaling sustains inflammation and promotes tumor development. J Exp Med 205(2):275–285CrossRef
66.
Barbel L-S, Markus S, Peter N, Angelika B (2007) RAGE signaling in cell adhesion and inflammation. Curr Pediatr Rev 3(1):1–9
67.
Sparvero Louis J, Denise A-A, Rui K, Daolin T, Neilay A, Jaehyun I, Ronnye R, Lin Brenda AAA, Zeh Herbert J (2009) RAGE (Receptor for Advanced Glycation endproducts), RAGE ligands, and their role in cancer and inflammation. J Transl Med 7(1):17PubMedPubMedCentralCrossRef
68.
Martinez-Outschoorn Ubaldo E, Curry Joseph M, Ying-Hui K, Lin Z, Madalina T, David C, Birbe Ruth C, Edmund P, Alessandro B, Pestell RG (2013) Oncogenes and inflammation rewire host energy metabolism in the tumor microenvironment: RAS and NFκB target stromal MCT4. Cell Cycle 12(16):2580–2597PubMedPubMedCentralCrossRef
69.
Masson Norma RPJ (2014) Hypoxia signaling pathways in cancer metabolism: the importance of co-selecting interconnected physiological pathways. Cancer Metab 2(1):3PubMedPubMedCentralCrossRef
70.
Sina G, Christian V, Philipp S, Doris M (2012) Hypoxia and HIF-1 increase S100A8 and S100A9 expression in prostate cancer. Int J Cancer 131(12):2785–2794CrossRef
71.
Masuko U-F, Yoshimasa N (2008) Reactive oxygen species and angiogenesis: NADPH oxidase as target for cancer therapy. Cancer Lett 266(1):37–52CrossRef
72.
Xuebo C, Leying Z, Zhang Ian Y, Junling L, Huaqing W, Mao O, Shihua W, Carvalho d FAC, Lihong W, Yasuhiko Y (2014) RAGE expression in tumor-associated macrophages promotes angiogenesis in glioma. Cancer Res 74(24):7285–7297CrossRef
73.
Huasheng L, Yuhua Z, Shaobi Z, Liang P (2011) Knockdown of RAGE expression inhibits colorectal cancer cell invasion and suppresses angiogenesis in vitro and in vivo. Cancer Lett 313(1):91–98CrossRef
74.
Wang W, Luo H-S, Yu B-P (2004) Expression of NF-κB and human telomerase reverse transcriptase in gastric cancer and precancerous lesions. World J Gastroenterol 10(2):177PubMedPubMedCentralCrossRef
75.
Masaharu A, Teru H, Toshiaki H, Yu-Tzu T, Mitsiades Constantine S, Nicholas M, Dharminder C, Paul R, Munshi Nikhil C, Anderson Kenneth C (2003) Nuclear factor-κB p65 mediates tumor necrosis factor α-induced nuclear translocation of telomerase reverse transcriptase protein. Cancer Res 63(1):18–21
76.
Chung LK, Vinay T (2013) Telomerase: central regulator of all of the hallmarks of cancer. Trends Biochem Sci 38(9):426–434CrossRef
77.
Lipinska Natalia, Romaniuk Aleksandra, Paszel-Jaworska Anna, Toton Ewa, Kopczynski Przemyslaw, Rubis Blazej. 2017. Telomerase and drug resistance in cancer. Cell Mol Life Sci:1–12
78.
Wang Julie C, Bennett Martin R. 2010. Nuclear factor-κΒ-mediated regulation of telomerase. Am Heart Assoc
79.
80.
Julio M, Li L, Fattah Farjana J, Ying D, Bey Erik A, Malina P, Jinming G, Boothman David A (2014) Review of poly(ADP-ribose) polymerase (PARP) mechanisms of action and rationale for targeting in cancer and other diseases. Crit Rev Eukaryot Gene Expr 24(1)
81.
Srikrishna Geetha FHH (2009) Endogenous damage-associated molecular pattern molecules at the crossroads of inflammation and cancer. Neoplasia 11(7):615–628PubMedPubMedCentralCrossRef
82.
Dara D, Wei-Xing Z, Thompson Craig B (2007) Activation of poly (ADP)-ribose polymerase (PARP-1) induces release of the pro-inflammatory mediator HMGB1 from the nucleus. J Biol Chem 282(24):17845–17854CrossRef
83.
Kang Rui, Xie Yangchun, Zhang Qiuhong, Hou Wen, Jiang Qingping, Zhu Shan, Liu Jinbao, Zeng Dexing, Wang Haichao, Bartlett David L. 2017. Intracellular HMGB1 as a novel tumor suppressor of pancreatic cancer. Cell Res
84.
Rui K, Qiuhong Z, Zeh Herbert J, Lotze Michael T, Daolin T (2013) HMGB1 in cancer: good, bad, or both? Clin Cancer Res 19(15):4046–4057CrossRef
85.
Rui K, Daolin T, Schapiro Nicole E, Livesey Kristen M, Adam F, Patricia L, Angelika B, Lotze Michael T, Zeh Herbert J (2010) The receptor for advanced glycation end products (RAGE) sustains autophagy and limits apoptosis, promoting pancreatic tumor cell survival. Cell Death Differ 17(4):666–676CrossRef
86.
Leclerc Estelle, Vetter Stefan W. 2015. The role of S100 proteins and their receptor RAGE in pancreatic cancer. BBA-Mol Basis Dis 1852 (12):2706–2711
87.
88.
Chonggao Y, Hongli L, Baogang Z, Yuqing L, Guohua L, Shijun L, Lei S, Yueliang Q, Xiaolong L, Weiyi C (2013) RAGE-binding S100A8/A9 promotes the migration and invasion of human breast cancer cells through actin polymerization and epithelial–mesenchymal transition. Breast Cancer Res Treat 142(2):297–309CrossRef
89.
Akihiko T, Blood David C, del Toro G, Anthony C, Lee Daniel C, Qu W, Nozomu T, Yan L, Evanthia L, Caifeng F (2000) Blockade of RAGE–amphoterin signalling suppresses tumour growth and metastases. Nature 405(6784):354–360CrossRef
90.
Dakhel S, Padilla L, Adan J, Masa M, Martinez JM, Roque L, Coll T, Hervas R, Calvis C, Messeguer R (2014) S100P antibody-mediated therapy as a new promising strategy for the treatment of pancreatic cancer. Oncogenesis 3(3):e92PubMedPubMedCentralCrossRef
91.
Hudson BI, Kalea AZ, del Mar AM, Harja E, Boulanger E, Vivette D'A, Schmidt AM (2008) Interaction of the RAGE cytoplasmic domain with diaphanous-1 is required for ligand-stimulated cellular migration through activation of Rac1 and Cdc42. J Biol Chem 283(49):34457–34468PubMedPubMedCentralCrossRef
92.
Martini M, De Santis MC, Braccinik L, Gulluni F, Hirsch E (2014) PI3K/AKT signaling pathway and cancer: an updated review. Ann Med 46(6):372–383PubMedCrossRef
93.
AL-Madhagi R, AL-Madhagi Y, Ma X, Juan Z, Cejun Y, Qiong D, Pengfei R, Ye B, Sheng L, Wei W (2013) Specific siRNA targeting receptor for advanced glycation end products (RAGE) decreases proliferation in human breast cancer cell lines. Int J Mol Sci 14(4):7959–7978CrossRef
94.
Roberts Patrick J, Der Channing J (2007) Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 26(22):3291–3310CrossRef
95.
Sylvain M, Jacques P (2007) The ERK1/2 mitogen-activated protein kinase pathway as a master regulator of the G1-to S-phase transition. Oncogene 26(22):3227–3239CrossRef
96.
San-Cher C, Jinn-Yuh G, Chi-Ching H, Shean-Jaw C, Tai-Du L, Yu-Ming K, Jau-Shyang H, Yu-Lin Y, Lea-Yea C (2010) Advanced glycation end-products activate extracellular signal-regulated kinase via the oxidative stress-EGF receptor pathway in renal fibroblasts. Journal of Cellular Biochemistry 109(1):38–48
97.
Qiu-Yu Z, Lin-Qing W, Zhang T, Yan-Fei H, Xu L (2015) Autophagy-mediated HMGB1 release promotes gastric cancer cell survival via RAGE activation of extracellular signal-regulated kinases 1/2. Oncol Rep 33(4):1630–1638CrossRef
98.
Thiruvengadam A, Logsdon Craig D (2011) S100P: a novel therapeutic target for cancer. Amino Acids 41(4):893–899CrossRef
99.
Holger Z, Stephan B, Thomas H, Jochen H, Oliver F, Michael L, Bernd W, Erbersdobler Helmut F, Sabine S, Busch Andreas E (2003) RAGE-mediated MAPK activation by food-derived AGE and non-AGE products. Biochem Biophys Res Commun 300(2):311–315CrossRef
100.
Kwak Taekyoung D-EK, Ergonul A, Miller PC, Braley A, Hwang GH, Zhao D, Besser A, Yamamoto Y, Yamamoto H (2017) Targeting of RAGE-ligand signaling impairs breast cancer cell invasion and metastasis. Oncogene 36(11):1559–1572CrossRef
101.
Indira E, Sivasakthivel T, Aoshuang C, Guoxing Z, Bosland Maarten C, André K-B, Munirathinam G (2012) Targeting receptor for advanced glycation end products (RAGE) expression induces apoptosis and inhibits prostate tumor growth. Biochem Biophys Res Commun 417(4):1133–1138CrossRef
102.
Ganju Ramesh K. 2013. Receptor for advanced glycation end products (RAGE) as a novel target for inhibiting breast cancer bone metastasis. Ohio state univ columbus
103.
Fara B-M, Simone F, Steven C, Rebecca M, Jelmar Q, Erika F-D, Plumb Darren A, Leila Z, Patrycja G, Gianmaria L (2016) PIM1 kinase regulates cell death, tumor growth and chemotherapy response in triple-negative breast cancer. Nat Med 22(11):1303–1313CrossRef
104.
Hardaway Aimalie L, Izabela P (2013) IL-1β, RAGE and FABP4: targeting the dynamic trio in metabolic inflammation and related pathologies. Future Med Chem 5(10):1089–1108PubMedCrossRef
105.
106.
Matsubara D, Niki T, Ishikawa S, Goto A, Ohara E, Yokomizo T, Heizmann CW, Aburatani H, Moriyama S, Moriyama H, Nishimura Y, Funata N, Fukayama M (2005) Differential expression of S100A2 and S100A4 in lung adenocarcinomas: clinicopathological significance, relationship to p53 and identification of their target genes. Cancer Sci 96(12):844–857. https://​doi.​org/​10.​1111/​j.​1349-7006.​2005.​00121.​x PubMedCrossRef
107.
108.
Elena C, Carla C, Annalisa M, Samanta T, Youssef S, Marcella P, Alessandra D’a, Caterina S, Giovanni S, Rosario C (2015) S100B-p53 disengagement by pentamidine promotes apoptosis and inhibits cellular migration via aquaporin-4 and metalloproteinase-2 inhibition in C6 glioma cells. Oncology Letters 9(6):2864–2870CrossRef
109.
Jing L, Qingyuan Y, Wilder Paul T, France C, Weber David J (2010) The calcium-binding protein S100B down-regulates p53 and apoptosis in malignant melanoma. J Biol Chem 285(35):27487–27498CrossRef
110.
Luis HJ, Laura P, Sheila D, Toni C, Rosa H, Jaume A, Marc M, Francesc M, Maria MJ, Silvia C (2013) Therapeutic targeting of tumor growth and angiogenesis with a novel anti-S100A4 monoclonal antibody. PLoS One 8(9):e72480CrossRef
111.
Lu Z, Da L, Yi-Ming Z, Yang H, Cheng D, Ma X-X (2016) Effects of receptor for advanced glycation endproducts on microvessel formation in endometrial cancer. BMC Cancer 16(1):93CrossRef
112.
June C, Koo LM, Kyoung Ho O, Soo KY, Young CH, Kuk BS, Yoon JK, Jeong-Soo W, Hoon LS, Young KS (2011) Interaction effect between the receptor for advanced glycation end products (RAGE) and high-mobility group box-1 (HMGB-1) for the migration of a squamous cell carcinoma cell line. Tumori 97(2):196–202CrossRef
113.
Lu Xin HJW, Erin P, Xiaoying S, Patricia T, Pingna D, Shan J, Qing C, Spring Denise J, Padmanee S (2017) Effective combinatorial immunotherapy for castration-resistant prostate cancer. Nature 543(7647):728–732PubMedPubMedCentralCrossRef
114.
Joseph M, Carson William E (2013) Review of S100A9 biology and its role in cancer. BBA-Rev Cancer 1835(1):100–109
115.
Ren X, Shao H, Wei Q, Sun Z, Liu N (2009) Advanced glycation end-products enhance calcification in vascular smooth muscle cells. J Int Med Res 37(3):847–854PubMedCrossRef
116.
Yukiko N, Yuji I, Yuka H, Jun-ichi K, Toshihiko N (2013) Advanced glycation end-products enhance calcification in cultured rat dental pulp cells. J Endod 39(7):873–878CrossRef
117.
118.
Yoray S, Yael R, Noam C, Amir B-S, Hila S, Tamar G, Neta E (2015) Tumor-derived osteopontin reprograms normal mammary fibroblasts to promote inflammation and tumor growth in breast cancer. Cancer Res 75(6):963–973CrossRef
119.
Vijayanirmala S, Muthukumar T, Malathi N, Rajan ST (2015) OPN—revisited. Journal of Clinical and Diagnostic Research: JCDR 9(6):ZE10
120.
121.
Weber Cynthia E, Kothari Anai N, Wai Philip Y, Li Neill Y, Joseph D, Zapf Matthew AC, Franzen Carrie A, Gupta Gopal N, Clodio O, Andrei Z (2015) Osteopontin mediates an MZF1–TGF-β1-dependent transformation of mesenchymal stem cells into cancer-associated fibroblasts in breast cancer. Oncogene 34(37):4821–4833CrossRef
122.
123.
Saleh S, Thompson DE, McConkey J, Murray P, Moorehead RA (2016) Osteopontin regulates proliferation, apoptosis, and migration of murine claudin-low mammary tumor cells. BMC Cancer 16(1):359PubMedPubMedCentralCrossRef
124.
Dhanashri T, Asutosh S, Reeti B, Kirti L, Sanjay D, Anupama M, Swapnil K, Suhaschandra D, Kundu Gopal C (2013) Association of osteopontin and cyclooxygenase-2 expression with breast cancer subtypes and their use as potential biomarkers. Oncol Lett 6(6):1559–1564CrossRef
125.
Bramwell Vivien HC, Tuck Alan B, Chapman Judith-Anne W, Anborgh Pieter H, Postenka Carl O, Waleed A-K, Shepherd Lois E, Lei H, Wilson Carolyn F, Pritchard KI (2014) Assessment of osteopontin in early breast cancer: correlative study in a randomised clinical trial. Breast Cancer Res 16(1):R8PubMedPubMedCentralCrossRef
126.
Bramwell Vivien HC, Doig Gordon S, Tuck Alan B, Wilson Sylvia M, Tonkin Katia S, Anna T, Francisco P, Vandenberg Theodore A, Chambers Ann F (2006) Serial plasma osteopontin levels have prognostic value in metastatic breast cancer. Clin Cancer Res 12(11):3337–3343PubMedCrossRef
127.
Abu E-AAM, Luc M, Karel G (2011) Expression of high-mobility groups box-1/receptor for advanced glycation end products/osteopontin/early growth response-1 pathway in proliferative vitreoretinal epiretinal membranes. Mol Vis 17:508
128.
Borthwick Lee A, Mann Derek A (2016) Liver: osteopontin and HMGB1: novel regulators of HSC activation. Nat Rev Gastroenterol Hepatol 13(6):320–322PubMedCrossRef
129.
Elena A, Ge X, Tung-Ming L, Fernando M, Aritz L, Yongke L, Naoto K, Raquel U, Neil T, Antoine Daniel J (2016) Signalling via the osteopontin and high mobility group box-1 axis drives the fibrogenic response to liver injury. In: Gut:gutjnl-2015-310752
130.
131.
Das Riku MGH, Kundu Gopal C (2003) Osteopontin stimulates cell motility and nuclear factor κB-mediated secretion of urokinase type plasminogen activator through phosphatidylinositol 3-kinase/Akt signaling pathways in breast cancer cells. J Biol Chem 278(31):28593–28606PubMedCrossRef
132.
Fernando O-M, Elena S, Eloy P-N, Ariadna P-B, Leire A, José S-P, Aranda Francisco I, Enrique L, Gloria P (2015) Osteopontin regulates VEGFA and ICAM-1 mRNA expression in breast carcinoma. Am J Clin Pathol 143(6):812–822CrossRef
133.
Monalisa B, Anuradha B, Ramesh B, Goutam C, Priyanka G, Pompom G, Mahadeo G, Smita K, Dhiraj K, Santosh K (2014) Osteopontin as a therapeutic target for cancer. Expert Opin Ther Targets 18(8):883–895CrossRef
134.
Mansoor A, Kundu Gopal C (2010) Osteopontin selectively regulates p70S6K/mTOR phosphorylation leading to NF-κB dependent AP-1-mediated ICAM-1 expression in breast cancer cells. Mol Cancer 9(1):101
135.
Reeti B, Vinit K, Kirti L, Swapnil K, Kundu Gopal C (2009) Activation of JAK2/STAT3 signaling by osteopontin promotes tumor growth in human breast cancer cells. Carcinogenesis 31(2):192–200
136.
Goutam C, Shalini J, Reeti B, Mansoor A, Priyanka S, Vinit K, Kundu Gopal C (2006) The multifaceted roles of osteopontin in cell signaling, tumor progression and angiogenesis. Curr Mol Med 6(8):819–830CrossRef
137.
Riku D, Mahabeleshwar Ganapati H, Kundu Gopal C (2004) Osteopontin induces AP-1-mediated secretion of urokinase-type plasminogen activator through c-Src-dependent epidermal growth factor receptor transactivation in breast cancer cells. J Biol Chem 279(12):11051–11064CrossRef
138.
Antje H, Henri W, Matthias K, Matthias K, Dirk V, Helge T, Matthias B (2010) Effects of osteopontin inhibition on radiosensitivityof MDA-MB-231 breast cancer cells. Radiat Oncol 5(1):82CrossRef
139.
140.
Atkinson RL, Yang WT, Rosen DG, Landis MD, Wong H, Lewis MT, Creighton CJ, Sexton KR, Hilsenbeck SG, Sahin AA, Brewster AM, Woodward WA, Chang JC (2013) Cancer stem cell markers are enriched in normal tissue adjacent to triple negative breast cancer and inversely correlated with DNA repair deficiency. Breast Cancer Research BCR 15(5):R77. https://​doi.​org/​10.​1186/​bcr3471 PubMedPubMedCentralCrossRef
141.
Stephen P (1889) The distribution of secondary growths in cancer of the breast. Lancet 133(3421):571–573CrossRef
142.
Mikuła-Pietrasik J, Paweł U, Andrzej T, Krzysztof K (2017) The peritoneal “soil” for a cancerous “seed”: a comprehensive review of the pathogenesis of intraperitoneal cancer metastases. Cell Mol Life Sci:1–17
143.
Thomas K, Emilia W, Sabine H-K, Ande Sudharsana R, Sebastian W, Klaus S-O, Marek L (2008) Cancer stem cell markers in common cancers—therapeutic implications. Trends Mol Med 14(10):450–460CrossRef
144.
145.
Yong L, Wang W-M, Xue-Lin Z, He H-Q, Xiao-Lei S, Hong Z, Xu X-F, Liang H, Zhu Z, Lei Z (2016) AGE/RAGE promotes thecalcification of human aortic smooth muscle cells via the Wnt/β-catenin axis. Am J Transl Res 8(11):4644
146.
Ulrike S, Franziska A, Janice S, Ulrike S, Pia H, Wolfgang W, Margit L, Iduna F, Shoemaker Robert H, Schlag Peter M (2011) Intervening in β-catenin signaling by sulindac inhibits S100A4-dependent colon cancer metastasis. Neoplasia 13(2):131–IN138CrossRef
147.
Ulrike S, Wolfgang W, Dominic S, Mike S, Jutta A, Clara L, Fichtner Iduna SPM, Shoemaker Robert H, Ulrike S (2011) S100A4-induced cell motility and metastasis is restricted by the Wnt/β-catenin pathway inhibitor calcimycin in colon cancer cells. Mol Biol Cell 22(18):3344–3354CrossRef
148.
Dexing F, David H, Yanhua Z, Yan X, Jill M, Heinz N, Mills Gordon B, Ryuji K, Tony H, Zhimin L (2007) Phosphorylation of β-catenin by AKT promotes β-catenin transcriptional activity. J Biol Chem 282(15):11221–11229CrossRef
149.
Goo L, Tatiana G, Elizabeth M, Ramanarao D, Pal SA, Brown Jeffrey B, Randal M, Yang G–Y, William RJ, Mark EB (2010) Phosphoinositide 3-kinase signaling mediates β-catenin activation in intestinal epithelial stem and progenitor cells in colitis. Gastroenterology 139(3):869–881. e869CrossRef
150.
Sho-ichi Y, Takanori M (2010) Advanced glycation end products, oxidative stress and diabetic nephropathy. Oxid Med Cell Longev 3(2):101–108CrossRef
151.
152.
153.
Xiang H, Yong C (2013) Possible participation of receptor for advanced glycation end products (RAGE) in the origin of cancer stem cells in diabetic patients with colon cancer. Med Hypotheses 80(5):620–623CrossRef
154.
Jeong-Hun K (2014). Protein kinase C (PKC) isozymes and cancer. New J Sci 2014 
155.
156.
Polina G, Alexander K, Nataliya B, Melania T, Isabelle P, Arnon N, Izhar H, Tsvee L (2006) cAMP-induced PKCζ activation increases functional CXCR4 expression on human CD34+ hematopoietic progenitors. Blood 107(3):870–879
157.
Suryatheja A, Abhilasha S, Mohamed EG, Simran B, Marshall Jr Gailen D, Gardner Lauren H, Yoshiko S, ElShamy Wael M (2016) Geminin overexpression-dependent recruitment and crosstalk with mesenchymal stem cells enhance aggressiveness in triple negative breast cancers. Oncotarget 7(15):20869
158.
Rihua Z, Xiaolin P, Huang Zuhu WGF, Guoxin Z (2011) Osteopontin enhances the expression and activity of MMP-2 via the SDF-1/CXCR4 axis in hepatocellular carcinoma cell lines. PLoS One 6(8):e23831CrossRef
159.
Das Shamik SRS, Shevde Lalita A (2011) Hedgehog signaling induced by breast cancer cells promotes osteoclastogenesis and osteolysis. J Biol Chem 286(11):9612–9622PubMedCrossRef
160.
Matteo P, Paola C (2010) Rac and rho GTPases in cancer cell motility control. Cell Commun Signal 8(1):23CrossRef
161.
Schiraldi M, Raucci A, Munoz LM, Livoti E, Celona B, Venereau E, Apuzzo T, De Marchis F, Pedotti M, Bachi A, Thelen M, Varani L, Mellado M, Proudfoot A, Bianchi ME, Uguccioni M (2012) HMGB1 promotes recruitment of inflammatory cells to damaged tissues by forming a complex with CXCL12 and signaling via CXCR4. J Exp Med 209(3):551–563. https://​doi.​org/​10.​1084/​jem.​20111739 PubMedPubMedCentralCrossRef
162.
Katrin K, Günter F (2013) RAGE regulation and signaling in inflammation and beyond. J Leukoc Biol 94(1):55–68CrossRef
163.
Sabine H-K, Suchitra N, Thatchawan T, Manoj M, Alok P, Saeid G, Thomas K (2014) Mechanisms of therapeutic resistance in cancer (stem) cells with emphasis on thyroid cancer cells. Front Endocrinol 5:37
164.
Laura C, Stefania L, Maddalena A, Roberta A, Enrico R, Daniela C, Calogero Raffaele A, Federica C (2013) The noninflammatory role of high mobility group box 1/Toll-like receptor 2 axis in the self-renewal of mammary cancer stem cells. The FASEB Journal 27(12):4731–4744CrossRef
165.
Aparna J, Bijay D, Steel Jason C (2016) Epithelial-to-mesenchymal plasticity of cancer stem cells: therapeutic targets in hepatocellular carcinoma. J Hematol Oncol 9(1):74CrossRef
166.
Takanobu T, Tadashi U, Akiko S-S, Masayoshi T (2017) Generation of glyceraldehyde-derived advanced glycation end-products in pancreatic cancer cells and the potential of tumor promotion. World J Gastroenterol 23(27):4910CrossRef
167.
Masayo M, Hidenori K, Yoshiko O, Tomoaki M, Katsuhito M, Takuhito S, Yohei M, Koka M, Shinya F, Atsushi S (2013) Receptor for advanced glycation end products regulates adipocyte hypertrophy and insulin sensitivity in mice: involvement of Toll-like receptor 2. Diabetes 62(2):478–489CrossRef
168.
Xiaolong M, Jie Z, Shuying L, Mollianne M, Gonzalez-Angulo AM (2012) A new hypothesis for the cancer mechanism. Cancer Metastasis Rev 31(1–2):247–268
169.
170.
171.
172.
Joseph M, MacKerell Alexander D, Weber David J (2007) A search for inhibitors of S100B, a member of the S100 family of calcium-binding proteins. Mini Rev Med Chem 7(6):609–616CrossRef
173.
Amlanjyoti D, Shampa M, Piya G, Atanu M, Israr A, Seemana B, Tapashi M, Asit M, Koushik R, Sandeep S (2014) Simultaneous inhibition of key growth pathways in melanoma cells and tumor regression by a designed bidentate constrained helical peptide. Pept Sci 102(4):344–358CrossRef
174.
Björk P, Björk A, Vogl T, Stenström M, Liberg D, Olsson A, Roth J, Ivars F, Leanderson T (2009) Identification of human S100A9 as a novel target for treatment of autoimmune disease via binding to quinoline-3-carboxamides. PLoS Biol 7(4):e1000097PubMedCentralCrossRef
175.
Pili R, Häggman M, Stadler WM, Gingrich JR, Assikis VJ, Björk A, Nordle Ö, Forsberg G, Carducci MA, Armstrong AJ (2011) Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer. J Clin Oncol 29(30):4022–4028PubMedCrossRef
176.
Hong Q, Beatrisa L, Ippei S, Guowei W, Cha Soungchul C, Rao Sheetal S, Jianfei Q, Yared H, Nurieva Roza DKC (2014) Generation of a new therapeutic peptide that depletes myeloid-derived suppressor cells in tumor-bearing mice. Nat Med 20(6):676–681CrossRef
177.
Limin Z, Haowen J, Gang X, Hui W, Bin G, Jun L, Shanghua M, Rong N, Yan J, Qiang D (2015) Proteins S100A8 and S100A9 are potential biomarkers for renal cell carcinoma in the early stages: results from a proteomic study integrated with bioinformatics analysis. Mol Med Rep 11(6):4093–4100CrossRef
178.
Filip P, Tomasz R, Yuzhu C, Tatjana C-J (2016) The life and works of S100P-from conception to cancer. Am J Cancer Res 6(2):562
179.
Thiruvengadam A, Vijaya R, Duoli S, Zhenghong P, Pal Ashutosh MDS, Bornmann William G, Logsdon Craig D (2013) Designing and developing S100P inhibitor 5-methyl cromolyn for pancreatic cancer therapy. Mol Cancer Ther 12(5):654–662CrossRef
180.
181.
Yuki K, Yoichi T, Tomoe K, Kouji K, Takahiko I, Tomoko H, Ichiaki I, Michiteru Y, Kengo S, Fumio S (2013) Identification and characterization of the direct interaction between methotrexate (MTX) and high-mobility group box 1 (HMGB1) protein. PLoS One 8(5):e63073CrossRef
182.
Takanori M, Sho-ichi Y, Masayoshi T, Seiji U, Kei F, Seiya O (2010) Nifedipine inhibits advanced glycation end products (AGEs) and their receptor (RAGE) interaction-mediated proximal tubular cell injury via peroxisome proliferator-activated receptor-gamma activation. Biochem Biophys Res Commun 398(2):326–330CrossRef
183.
Jie C, Xiaoyan L, Jie Z, Yueran Z (2012) Targeting HMGB1 inhibits ovarian cancer growth and metastasis by lentivirus-mediated RNA interference. J Cell Physiol 227(11):3629–3638CrossRef
184.
Dong Y-D, Cui L, Peng C-H, Cheng D-F, Han B-S, Fang H (2013) Expression and clinical significance of HMGB1 in human liver cancer: knockdown inhibits tumor growth and metastasis in vitro and in vivo. Oncol Rep 29(1):87–94PubMedCrossRef
185.
Huang Z, Zhong Z, Zhang L, Wang X, Xu R, Zhu L, Wang Z, Hu S, Zhao X (2015) Down-regulation of HMGB1 expression by shRNA constructs inhibits the bioactivity of urothelial carcinoma cell lines via the NF-κB pathway. Sci Rep 5
186.
Laura P, Xue J, David L, Sandra P, Sandro J, Forest Kelly H, Saad-Jube Zeyana S, Napolitano A, Pagano I, Negi VS (2017) HMGB1 targeting by ethyl pyruvate suppresses malignant phenotype of human mesothelioma. Oncotarget 8(14):22649CrossRef
187.
Li ML, Wang XF, Tan ZJ, Dong P, Gu J, Lu JH, Wu XS, Zhang L, Ding QC, Wu WG (2012) Ethyl pyruvate administration suppresses growth and invasion of gallbladder cancer cells via downregulation of HMGB1-RAGE axis. Int J Immunopathol Pharmacol 25(4):955–965PubMedCrossRef
188.
Shen M, Lu J, Dai W, Wang F, Xu L, Chen K, He L, Cheng P, Zhang Y, Wang C (2013) Ethyl pyruvate ameliorates hepatic ischemia-reperfusion injury by inhibiting intrinsic pathway of apoptosis and autophagy. Mediat Inflamm 2013
189.
Du G-J, Zhiyu Z, Xiao-Dong W, Yu C, Tyler C, Chun-Su Y, Wang C-Z (2012) Epigallocatechin Gallate (EGCG) is the most effective cancer chemopreventive polyphenol in green tea. Nutrients 4(11):1679–1691PubMedPubMedCentralCrossRef
190.
191.
Li W, Ashok M, Li J, Yang H, Sama AE, Wang H (2007) A major ingredient of green tea rescues mice from lethal sepsis partly by inhibiting HMGB1. PLoS One 2(11):e1153PubMedPubMedCentralCrossRef
192.
Mollica L, De Marchis F, Spitaleri A, Dallacosta C, Pennacchini D, Zamai M, Agresti A, Trisciuoglio L, Musco G, Bianchi ME (2007) Glycyrrhizin binds to high-mobility group box 1 protein and inhibits its cytokine activities. Chem Biol 14(4):431–441PubMedCrossRef
193.
Smolarczyk R, Cichoń T, Matuszczak S, Mitrus I, Lesiak M, Kobusińska M, Kamysz W, Jarosz M, Sieroń A, Szalak S (2012) The role of glycyrrhizin, an inhibitor of HMGB1 protein, in anticancer therapy. Archivum Immunologiae Et Therapiae Experimentalis 60(5):391–399PubMedCrossRef
194.
Dhumale SS, Waghela BN, Pathak C (2015) Quercetin protects necrotic insult and promotes apoptosis by attenuating the expression of RAGE and its ligand HMGB1 in human breast adenocarcinoma cells. IUBMB Life 67(5):361–373PubMedCrossRef
195.
Julius A, Hopper W (2017) Inhibition of advanced glycation end-product formation by quercetin and catechin: an alternative therapy for treating diabetic complications. Asian J Pharm Clin Res 10(11):173–176CrossRef
196.
Tang Y, Chen A (2014) Curcumin eliminates the effect of advanced glycation end-products (AGEs) on the divergent regulation of gene expression of receptors of AGEs by interrupting leptin signaling. Lab Investig 94(5):503–516PubMedCrossRef
197.
Lin J, Tang Y, Kang Q, Feng Y, Chen A (2012) Curcumin inhibits gene expression of receptor for advanced glycation end-products (RAGE) in hepatic stellate cells in vitro by elevating PPARγ activity and attenuating oxidative stress. Br J Pharmacol 166(8):2212–2227PubMedPubMedCentralCrossRef
198.
Wang C, Nie H, Li K, Zhang Y-x, Yang F, Li C-b, Wang C-f, Gong Q (2012) Curcumin inhibits HMGB1 releasing and attenuates concanavalin A-induced hepatitis in mice. Eur J Pharmacol 697(1):152–157PubMedCrossRef
199.
Kim D-C, Lee W, Bae J-S (2011) Vascular anti-inflammatory effects of curcumin on HMGB1-mediated responses in vitro. Inflamm Res 60(12):1161–1168PubMedCrossRef
200.
Vinod BS, Antony J, Nair HH, Puliyappadamba VT, Saikia M, Narayanan SS, Bevin A, Anto RJ (2013) Mechanistic evaluation of the signaling events regulating curcumin-mediated chemosensitization of breast cancer cells to 5-fluorouracil. Cell Death Dis 4(2):e505PubMedPubMedCentralCrossRef
201.
202.
Mizumoto S, Takahashi J, Kazuyuki S (2012) Receptor for advanced glycation end products (RAGE) functions as receptor for specific sulfated glycosaminoglycans, and anti-RAGE antibody or sulfated glycosaminoglycans delivered in vivo inhibit pulmonary metastasis of tumor cells. J Biol Chem 287(23):18985–18994PubMedPubMedCentralCrossRef
203.
Bongarzone S, Savickas V, Luzi F, Gee AD (2017) Targeting the receptor for advanced glycation endproducts (RAGE): a medicinal chemistry perspective. J Med Chem
204.
Arumugam T, Ramachandran V, Gomez SB, Schmidt Ann M, Logsdon CD (2012) S100P-derived RAGE antagonistic peptide reduces tumor growth and metastasis. Clin Cancer Res 18(16):4356–4364PubMedCrossRef
205.
206.
Nakamura K, Yamagishi S-i, Nakamura Y, Takenaka K, Matsui T, Jinnouchi Y, Imaizumi T (2005) Telmisartan inhibits expression of a receptor for advanced glycation end products (RAGE) in angiotensin-II-exposed endothelial cells and decreases serum levels of soluble RAGE in patients with essential hypertension. Microvasc Res 70(3):137–141PubMedCrossRef
207.
Chen X-F, Zou J-J, Tang W, Lin W-D, Sun L-L, Bao Y, Chen H-Y, Zhang B, Ye F, Liu Z-M (2016) Metformin corrects RAGE overexpression caused signaling dysregulation and NF-κB targeted gene change. Int J Clin Exp Med 9(2):2913–2920
208.
Kumar AA, Hayati ON, Subramani P, Urmila B (2017) Curcumin: the spicy modulator of breast carcinogenesis. J Exp Clin Cancer Res 36(1):98CrossRef
209.
Zhang G, Xue Y-m, GAO F, Zhu B (2010) AGE-RAGE interaction promotes the proliferation of human colon carcinoma SW-480 cells [J]. Journal of Medical Postgraduates 9:008
210.
Sun YP, Gu JF, Tan X, Bin WCF, Jia XB, Feng L, Liu JP (2016) Curcumin inhibits advanced glycation end product-induced oxidative stress and inflammatory responses in endothelial cell damage via trapping methylglyoxal. Mol Med Rep 13(2):1475–1486PubMedCrossRef
211.
Shen Y, Xu Z, Sheng Z (2017) Ability of resveratrol to inhibit advanced glycation end product formation and carbohydrate-hydrolyzing enzyme activity and to conjugate methylglyoxal. Food Chem 216:153–160PubMedCrossRef
212.
Moridi H, Karimi J, Sheikh N, Goodarzi MT, Saidijam M, Yadegarazari R, Khazaei M, Khodadadi I, Tavilani H, Piri H (2015) Resveratrol-dependent down-regulation of receptor for advanced glycation end-products and oxidative stress in kidney of rats with diabetes. Int J Endocrinol Metab 13(2)
213.
Singh CK, Ndiaye MA, Ahmad N (2015) Resveratrol and cancer: challenges for clinical translation. Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease 1852(6):1178–1185CrossRef
214.
Lv L, Shao X, Chen H, Ho C-T, Sang S (2011) Genistein inhibits advanced glycation end product formation by trapping methylglyoxal. Chem Res Toxicol 24(4):579–586PubMedCrossRef
215.
Russo M, Russo GL, Daglia M, Kasi PD, Ravi S, Nabavi SF, Nabavi SM (2016) Understanding genistein in cancer: the “good” and the “bad” effects: a review. Food Chem 196:589–600PubMedCrossRef
216.
Saadat Nadia, Gupta Smiti V (2012). Potential role of garcinol as an anticancer agent. J Oncol 2012
217.
Fumio Y, Toshiaki A, Yoshihiro Y, Hiroyuki N (2000) Antioxidative and anti-glycation activity of garcinol from Garcinia indica fruit rind. J Agric Food Chem 48(2):180–185CrossRef
218.
219.
220.
221.
Gu H, Yang L, Sun Q, Zhou B, Tang N, Cong R, Zeng Y, Wang B (2008) Gly82Ser polymorphism of the receptor for advanced glycation end products is associated with an increased risk of gastric cancer in a Chinese population. Clin Cancer Res 14(11):3627–3632PubMedCrossRef
222.
Park SJ, Kleffmann T, Hessian PA (2011) The G82S polymorphism promotes glycosylation of the receptor for advanced glycation end products (RAGE) at asparagine 81 comparison of wild-type rage with the g82s polymorphic variant. J Biol Chem 286(24):21384–21392PubMedPubMedCentralCrossRef
223.
Wang X, Cui E, Zeng H, Hua F, Wang B, Mao W, Feng X (2012) RAGE genetic polymorphisms are associated with risk, chemotherapy response and prognosis in patients with advanced NSCLC. PLoS One 7(10):–e43734
224.
Pan Hongming, He Lan, Wang Bin, Niu Wenquan. 2014. The relationship between RAGE gene four common polymorphisms and breast cancer risk in northeastern Han Chinese. Sci Rep 4
225.
Qian F, Sun BL, Zhang WY, Ke J, Zhu J (2014) Gly82Ser polymorphism of the receptor for advanced glycation end-product (RAGE) potential high risk in patients with colorectal cancer. Tumor Biol 35(4):3171–3175CrossRef
226.
Su SC, Hsieh MJ, Chou YE, Fan WL, Yeh CB, Yang SF (2015) Effects of RAGE gene polymorphisms on the risk and progression of hepatocellular carcinoma. Medicine 94(34):e1396PubMedPubMedCentralCrossRef
227.
Su S, Chien M, Lin C, Chen M, Yang S (2015) RAGE gene polymorphism and environmental factor in the risk of oral cancer. J Dent Res 94(3):403–411PubMedPubMedCentralCrossRef
228.
Xia W, Xu Y, Mao Q, Dong G, Shi R, Wang J, Zheng Y, Xu L, Jiang F (2015) Association of RAGE polymorphisms and cancer risk: a meta-analysis of 27 studies. Med Oncol 32(2):33CrossRef
229.
Zhao D-C, Lu H-W, Huang Z-H (2015) Association between the receptor for advanced glycation end products gene polymorphisms and cancer risk: a systematic review and meta-analysis. J buon 20:614–624PubMed
230.
Liu S, Tong X, He M, Fu X, Zhang Y, Fan H (2016) The receptor for advanced glycation end products gene polymorphisms contribute to cancer susceptibility: evidence from meta-analysis. Int J Clin Exp Med 9(3):5867–5879
231.
Yue L, Zhang Q, He L, Zhang M, Dong J, Zhao D, Ma H, Pan H, Zheng L (2016) Genetic predisposition of six well-defined polymorphisms in HMGB1/RAGE pathway to breast cancer in a large Han Chinese population. J Cell Mol Med 20(10):1966–1973PubMedPubMedCentralCrossRef
232.
Taijie L, Weijuan Q, Yanqiong L, Shan L, Xue Q, Zhiming L (2017) Effect of RAGE gene polymorphisms and circulating sRAGE levels on susceptibility to gastric cancer: a case–control study. Cancer Cell Int 17(1):19CrossRef
233.
Gaens KH, Ferreira I, van der Kallen Carla JH, van Greevenbroek Marleen MJ, Blaak Ellen E, Feskens Edith JM, Dekker Jacqueline M, Giel N, Heine Robert J, ‘t Hart Leen M (2009) Association of polymorphism in the receptor for advanced glycation end products (RAGE) gene with circulating RAGE levels. J Clin Endocrinol Metabol 94(12):5174–5180CrossRef
234.
Kalea AZ, Schmidt AM, Hudson BI (2009) RAGE: a novel biological and genetic marker for vascular disease. Clin Sci 116(8):621–637CrossRef
235.
Hofmann MA, Drury S, Hudson BI, Gleason MR, Qu W, Lu Y, Lalla E, Chitnis S, Monteiro J, Stickland MH (2002) RAGE and arthritis: the G82S polymorphism amplifies the inflammatory response. Genes Immun 3(3):123PubMedCrossRef
236.
237.
Geroldi D, Falcone C, Minoretti P, Emanuele E, Arra M, D'angelo A (2006) High levels of soluble receptor for advanced glycation end products may be a marker of extreme longevity in humans. J Am Geriatr Soc 54(7):1149–1150PubMedCrossRef
238.
Li S, Li T, Qin W, Qin X, Liu Y, Liu Z (2017) Effect of RAGE gene polymorphisms and circulating sRAGE levels on susceptibility to gastric cancer: a case–control study. Cancer Cell Int 17(1):19PubMedPubMedCentralCrossRef
239.
Tomáš K, Marie J, Oto M, Aleš Ž, Tomáš Z, Marta K (2010) Soluble receptor for advanced glycation end-products (sRAGE) and polymorphisms of RAGE and glyoxalase I genes in patients with pancreas cancer. Clin Biochem 43(10–11):882–886
240.
Jing R, Cui M, Wang J, Wang H (2010) Receptor for advanced glycation end products (RAGE) soluble form (sRAGE): a new biomarker for lung cancer. Neoplasma 57(1):55–61PubMedCrossRef
241.
242.
243.
Boor P, Celec P, Klenovicsova K, Vlkova B, Szemes T, Minarik G, Turňa J, Šebeková K (2010) Association of biochemical parameters and RAGE gene polymorphisms in healthy infants and their mothers. Clin Chim Acta 411(15–16):1034–1040PubMedCrossRef
244.
Sasahira T, Kirita T, Bhawal UK, Yamamoto K, Ohmori H, Fujii K, Kuniyasu H (2007) Receptor for advanced glycation end products (RAGE) is important in the prediction of recurrence in human oral squamous cell carcinoma. Histopathology 51(2):166–172PubMedCrossRef
245.
Zhao C-B, Bao J-M, Lu Y-J, Zhao T, Zhou X-H, Zheng D-Y, Shan-Chao Z (2014) Co-expression of RAGE and HMGB1 is associated with cancer progression and poor patient outcome of prostate cancer. Am J Cancer Res 4(4):369PubMedPubMedCentral
246.
Diederichs, Sven, Bulk, Etmar, Steffen, Björn, Ji, Ping, Tickenbrock, Lara, Lang Kerstin, Zänker Kurt S, Metzger, Ralf, Schneider Paul M, Gerke Volker. 2004. S100 family members and trypsinogens are predictors of distant metastasis and survival in early-stage non-small cell lung cancer. Cancer Res 64 (16):5564–5569
247.
248.
249.
250.
251.
252.
Metadaten
Titel
RAGE and Its Ligands: Molecular Interplay Between Glycation, Inflammation, and Hallmarks of Cancer—a Review
verfasst von
Gowri Palanissami
Solomon F. D. Paul
Publikationsdatum
09.07.2018
Verlag
Springer US
Erschienen in
Discover Oncology / Ausgabe 5/2018
Print ISSN: 1868-8497
Elektronische ISSN: 2730-6011
DOI
https://doi.org/10.1007/s12672-018-0342-9

Weitere Artikel der Ausgabe 5/2018

Discover Oncology 5/2018 Zur Ausgabe

Original Paper

Nano-Diamino-Tetrac (NDAT) Enhances Resveratrol-Induced Antiproliferation by Action on the RRM2 Pathway in Colorectal Cancers

Original Paper

RNA Sequencing of Carboplatin- and Paclitaxel-Resistant Endometrial Cancer Cells Reveals New Stratification Markers and Molecular Targets for Cancer Treatment

Original Paper

Impact of Gender and Age on the Prognosis of Differentiated Thyroid Carcinoma: a Retrospective Analysis Based on SEER

Original Paper

Increased High Molecular Weight FGF2 in Endocrine-Resistant Breast Cancer

Neu im Fachgebiet Onkologie

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Perioperative Checkpointhemmer-Therapie verbessert NSCLC-Prognose

28.05.2024 NSCLC Nachrichten

Eine perioperative Therapie mit Nivolumab reduziert das Risiko für Rezidive und Todesfälle bei operablem NSCLC im Vergleich zu einer alleinigen neoadjuvanten Chemotherapie um über 40%. Darauf deuten die Resultate der Phase-3-Studie CheckMate 77T.

Positiver FIT: Die Ursache liegt nicht immer im Dickdarm

27.05.2024 Blut im Stuhl Nachrichten

Immunchemischer Stuhltest positiv, Koloskopie negativ – in solchen Fällen kann die Blutungsquelle auch weiter proximal sitzen. Ein Forschungsteam hat nachgesehen, wie häufig und in welchen Lokalisationen das der Fall ist.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise